Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

OBJECTIVE: The choice of chemotherapeutic regimen for triple-negative breast cancer (TNBC) remains controversial. Homologous recombination deficiency (HRD) has attracted increasing attention in informing chemotherapy treatment. This study was aimed at investigating the feasibility of HRD as a clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yimeng, Wang, Xue, Du, Feng, Yue, Jian, Si, Yiran, Zhao, Xiaochen, Cui, Lina, Zhang, Bei, Bei, Ting, Xu, Binghe, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978893/
https://www.ncbi.nlm.nih.gov/pubmed/36861447
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978893/
https://www.ncbi.nlm.nih.gov/pubmed/36861447
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0525

Ejemplares similares